Adaptimmune sets terms for $150M IPO; BioMarin completes app for DMD drug drisapersen;

@FierceBiotech: Biogen partner Sobi and its Boston-based CEO field a takeover bid. News | Follow @FierceBiotech

@JohnCFierce: No, $BLUE is not $CLDN. Not hard to separate these companies' technology/pipelines. | Follow @JohnCFierce

@DamianFierce: tal im' oh jeen la her" pa rep' vek. Amgen file | Follow @DamianFierce

> Adaptimmune has set terms for its closely watched IPO, planning to sell 9.4 million shares at $15 to $17 a share. The UK biotech is looking to raise about $150 million on Nasdaq with its cancer immunotherapies using T-cell receptor tech. Story

> BioMarin ($BMRN) says it has completed its rolling NDA for drisapersen, its exon-skipping Duchenne muscular dystrophy drug. Drisapersen has an orphan drug designation alongside a breakthrough therapy title at the FDA. With that kind of pedigree, a marketing decision could come before the end of this year. Release

> San Francisco-based 4D Molecular Therapeutics inks a deal with Roche ($RHHBY) to discover and develop next-generation AAV gene delivery vectors. Release

Medical Device News

@FierceMedDev: ICYMI from FierceDiagnostics: Veracyte unveils $40M private placement to generate cash for R&D. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Updated w/ $MDT comment: Medtronic facing new wrongful death lawsuit over failed insulin pump in wake of 2009 recall. More | Follow @VarunSaxena2

@EmilyWFierce: Neuronetics raised $34.3M in a Series F round led by $GE for noninvasive magnetic stimulation device for depression. More from the WSJ | Follow @EmilyWFierce

> Sorin Group touts study showing its flexible implant for mitral valve disease is better than Medtronic's. More

> Spectranetics shares slump as the medical laser maker snips forecast. Story

> Boston Scientific loses bid to throw out claims tied to vaginal mesh device. Report

Pharma News

@FiercePharma: Mylan Board Unanimously Rejects Unsolicited Expression of Interest from Teva. Release | Follow @FiercePharma

@EricPFierce: Lilly's Elanco unloading Novartis California vax plant it picked up in animal health deal. FiercePharmaManufacturing report | Follow @EricPFierce

@CarlyHFierce: Mylan Board Unanimously Rejects Unsolicited Expression of Interest from Teva. Release | Follow @CarlyHFierce

> Roche, Amgen, Novo top the ranks in biologics sales, with AbbVie, Sanofi close behind. Story

> What price MS therapy? Thanks to price hikes, $50K-plus, even for decades-old meds. More

Animal Health News

> Bayer closes MO animal health plant, citing excess capacity. News

> New study warns you can catch diseases from your pets. Story

> Lilly beats estimates on newly bulked-up animal health unit. Item

> Fallout continues in wake of avian bird flu spreading across the U.S. More

> Dog data at AACR cancer confab may point to personalized treatments. Report

Biotech IT News

> Quest, LabCorp team to build database of cancer genetics. News

> Edico and Intel set sights on real-time whole genome analysis. More

> Lilly, Novartis and Pfizer give trial-patient matching tech to TrialReach. Report

> WuXi invests $15M in DNAnexus to fuel push into China. Story

> AstraZeneca tightens ties to Roche's informatics platform provider. Article

Suggested Articles

The biotech behind AstraZeneca and the University of Oxford’s late-stage pandemic vaccine has hired Margaret (Meg) Marshall, M.D., as its new CMO.

On the heels of a merger and $60 million private offering, Compass is looking to go public. It filed to raise up to $50 million in its Nasdaq IPO.

he results suggest V114 provides broader protection from pneumococcal bacteria than Prevnar 13 does, positioning Merck to muscle in on Pfizer’s turf.